18th Mar 2021 14:02
SkinBioTherapeutics plc
Significant Shareholder
Manchester, UK - 18 March 2021 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, provides an update on the shareholding of OptiBiotix Health Plc ("OptiBiotix") in the Company.
As part of the Placing and Open Offer announced 30 October 2020, the Company, OptiBiotix and Cenkos Securities plc ("Cenkos"), entered into a lock-in and orderly market agreement pursuant to which OptiBiotix agreed to certain undertakings. On 12 March 2021 OptiBiotix approached the Company and Cenkos seeking consent to sell two million shares in the Company. Noting the high demand for SBTX shares, the Company and Cenkos consented to the sale of the shares subject to maintaining an orderly market.
Consequent to the disposal of shares, OptiBiotix's holding in the Company has reduced to 36,138,569 shares representing 23.2% of the issued share capital.
All parties are committed to maintaining the terms of the lock-in agreement for the remainder of its term and there is no expectation that a further consent request will be made by or granted to OptiBiotix.
TR-1: Standard form for notification of major holdings
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: | SkinBioTherapeutics plc Company No: 09632164 (England)
| |||||
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
Non-UK issuer |
| |||||
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | X | |||||
An acquisition or disposal of financial instruments |
| |||||
An event changing the breakdown of voting rights |
| |||||
Other (please specify)iii: |
| |||||
3. Details of person subject to the notification obligationiv | ||||||
Name | Optibiotix Health PLC | |||||
City and country of registered office (if applicable) | York (UK) | |||||
4. Full name of shareholder(s) (if different from 3.)v | ||||||
Name |
| |||||
City and country of registered office (if applicable) |
| |||||
5. Date on which the threshold was crossed or reachedvi: | 17 March 2021 | |||||
6. Date on which issuer notified (DD/MM/YYYY): | 18 March 2021 | |||||
7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments(total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights of issuervii | ||
Resulting situation on the date on which threshold was crossed or reached | 23.18 |
| 23.18 | 155,889,922 | ||
Position of previous notification (if applicable) | 24.46 |
| 24.46 |
| ||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii | |||||||||
A: Voting rights attached to shares | |||||||||
Class/type ofshares ISIN code (if possible) | Number of voting rightsix | % of voting rights | |||||||
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | ||||||
Ordinary | 36,138,569 |
| 23.18 |
| |||||
|
|
|
|
| |||||
|
|
|
|
| |||||
SUBTOTAL 8. A | 36,138,569 | 23.18 | |||||||
| |||||||||
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||
Type of financial instrument | Expirationdatex | Exercise/Conversion Periodxi | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
|
|
|
|
| |||||
|
|
|
|
| |||||
|
|
|
|
| |||||
|
| SUBTOTAL 8. B 1 |
|
| |||||
| |||||||||
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||
Type of financial instrument | Expirationdatex | Exercise/Conversion Period xi | Physical or cash settlementxii | Number of voting rights | % of voting rights | ||||
|
|
|
|
|
| ||||
|
|
|
|
|
| ||||
|
|
|
|
|
| ||||
|
|
| SUBTOTAL 8.B.2 |
|
| ||||
| |||||||||
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii | X | |||
Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) |
| |||
Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
| ||||
10. In case of proxy voting, please identify: | ||||
Name of the proxy holder |
| |||
The number and % of voting rights held |
| |||
The date until which the voting rights will be held |
| |||
| ||||
11. Additional informationxvi | ||||
Change due to sale of shares | ||||
Place of completion | Edinburgh |
Date of completion | 18 March 2021 |
-Ends-
For more information, please contact:
SkinBioTherapeutics plcStuart J. Ashman, CEODoug Quinn, CFO | Tel: +44 (0) 161 468 2760 |
|
|
Cenkos Securities Plc (Nominated Adviser & Broker)Giles Balleny, Max Gould (Corporate Finance)Michael Johnson (Sales) | Tel: +44 (0) 20 7397 8900 |
|
|
Instinctif PartnersMelanie Toyne-Sewell / Phillip Marriage / Nathan Billis | Tel: +44 (0) 20 7457 2020[email protected] |
Related Shares:
Skinbiotherap.